Latham & Watkins Advises Underwriters in CureVac’s US$450 Million Follow-on Public Offering of Common Shares

Capital markets team represented the underwriters in the offering by the global biopharmaceutical company.

January 28, 2021

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has announced the pricing of its follow-on public offering of 5 million common shares at a public offering price of US$90 per common share, for total gross proceeds of approximately US$450 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 750,000 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by CureVac. The offering is expected to close on February 1, 2021, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Adam Johnson, Patrick Maguire, and MacLane Taggart.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.